Anderson A, Conley P, Klocke C, Sengupta S, Pang A, Farley H
Biomark Res. 2024; 12(1):67.
PMID: 39030653
PMC: 11264923.
DOI: 10.1186/s40364-024-00609-6.
Zheng Y, Tang Y, Yao Y, Ge T, Pan H, Cui J
Invest Ophthalmol Vis Sci. 2024; 65(8):3.
PMID: 38953846
PMC: 11221615.
DOI: 10.1167/iovs.65.8.3.
Fuentes-Rodriguez A, Mitchell A, Guerin S, Landreville S
Cells. 2024; 13(12.
PMID: 38920653
PMC: 11201764.
DOI: 10.3390/cells13121023.
Boe M, Vicari S, Boccatonda A, Piscaglia F
J Ultrasound. 2024; 27(4):927-934.
PMID: 38864955
PMC: 11496420.
DOI: 10.1007/s40477-024-00909-5.
Pasarica M, Curca P, Dragosloveanu C, Grigorescu A, Nisipasu C
Diagnostics (Basel). 2024; 14(9).
PMID: 38732371
PMC: 11083017.
DOI: 10.3390/diagnostics14090958.
Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior.
Pawlik V, Sonntag S, Grisanti S, Tura A, Kakkassery V, Ranjbar M
Invest Ophthalmol Vis Sci. 2024; 65(2):30.
PMID: 38381412
PMC: 10893901.
DOI: 10.1167/iovs.65.2.30.
Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma.
Anderson A, Conley P, Klocke C, Sengupta S, Pang A, Farley H
Res Sq. 2023; .
PMID: 38106024
PMC: 10723549.
DOI: 10.21203/rs.3.rs-3694879/v1.
The use of RNA-based treatments in the field of cancer immunotherapy.
Chehelgerdi M, Chehelgerdi M
Mol Cancer. 2023; 22(1):106.
PMID: 37420174
PMC: 10401791.
DOI: 10.1186/s12943-023-01807-w.
Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients.
Machiraju D, Hassel J
Front Oncol. 2023; 12:1068029.
PMID: 36761417
PMC: 9902905.
DOI: 10.3389/fonc.2022.1068029.
Role of Fibroblast Growth Factors in the Crosstalk of Hepatic Stellate Cells and Uveal Melanoma Cells in the Liver Metastatic Niche.
Seitz T, John N, Sommer J, Dietrich P, Thasler W, Hartmann A
Int J Mol Sci. 2022; 23(19).
PMID: 36232829
PMC: 9569506.
DOI: 10.3390/ijms231911524.
Enhancing the immune effect of oHSV-1 therapy through TLR3 signaling in uveal melanoma.
Liu S, Li M, Sun F, Zhang J, Liu F
J Cancer Res Clin Oncol. 2022; 149(2):901-912.
PMID: 36030435
DOI: 10.1007/s00432-022-04272-y.
The future of targeted kinase inhibitors in melanoma.
Caksa S, Baqai U, Aplin A
Pharmacol Ther. 2022; 239:108200.
PMID: 35513054
PMC: 10187889.
DOI: 10.1016/j.pharmthera.2022.108200.
Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma.
Baqai U, Purwin T, Bechtel N, Chua V, Han A, Hartsough E
Mol Cancer Res. 2022; 20(8):1260-1271.
PMID: 35426938
PMC: 9357204.
DOI: 10.1158/1541-7786.MCR-21-0657.
SLC25A38 as a novel biomarker for metastasis and clinical outcome in uveal melanoma.
Fan Z, Duan J, Luo P, Shao L, Chen Q, Tan X
Cell Death Dis. 2022; 13(4):330.
PMID: 35411037
PMC: 9001737.
DOI: 10.1038/s41419-022-04718-8.
Visualized Tracking of Tumor-Derived Extracellular Vesicles Using CRISPR-Cas9 System.
Ye Y, Shi Q, Yang T, Xie F, Zhang X, Xu B
Technol Cancer Res Treat. 2022; 21:15330338221085370.
PMID: 35315725
PMC: 8943546.
DOI: 10.1177/15330338221085370.
The Effect of Intraocular Pressure-Lowering Medication on Metastatic Uveal Melanomas.
Pals J, Mensink H, Brosens E, Verdijk R, Naus N, Paridaens D
Cancers (Basel). 2021; 13(22).
PMID: 34830810
PMC: 8616129.
DOI: 10.3390/cancers13225657.
Potential of miRNA-Based Nanotherapeutics for Uveal Melanoma.
Yang C, Wang R, Hardy P
Cancers (Basel). 2021; 13(20).
PMID: 34680340
PMC: 8534265.
DOI: 10.3390/cancers13205192.
The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival.
Dewaele S, Delhaye L, De Paepe B, de Bony E, De Wilde J, Vanderheyden K
Oncogene. 2021; 41(1):15-25.
PMID: 34508176
PMC: 8724009.
DOI: 10.1038/s41388-021-02006-x.
Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.
Soltantoyeh T, Akbari B, Karimi A, Chalbatani G, Ghahri-Saremi N, Hadjati J
Cells. 2021; 10(6).
PMID: 34207884
PMC: 8230324.
DOI: 10.3390/cells10061450.
Exploring the role of BAFF as biomarker in the detection of uveal melanoma metastases.
Lin Z, Susskind D
J Cancer Res Clin Oncol. 2021; 147(5):1389-1405.
PMID: 33665679
DOI: 10.1007/s00432-021-03555-0.